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Objectives: To assess the efﬁciency of a systematically planned compression ultrasonography (SP-CUS) to
detect venous thrombotic complications (VTCs) in patients with symptomatic isolated superﬁcial vein
thrombosis (SVT).
Design: Post hoc analysis of a prospective, multicentre, cohort study (POST).
Patients: As many as 537 patients with CUS-conﬁrmed isolated SVT undergoing an SP-CUS 8e15 days
after the initial CUS.
Outcomes: Asymptomatic VTC (extension or recurrence of SVT, deep-vein thrombosis (DVT) of the lower
limbs) diagnosed by the SP-CUS and symptomatic thromboembolic complications (VTC and pulmonary
embolism (PE)) up to 3 months.
Results: VTC was suspected before or on the day of the SP-CUS in 18 patients (3.0%). Among the 519
asymptomatic patients (97%) undergoing SP-CUS, this revealed asymptomatic VTC in 12 patients (2.3%; 4
DVT, 4 SVT recurrences, 4 SVT extensions), none of whom subsequently experienced symptomatic
thromboembolic events up to 3 months. Among the 507 patients with a normal SP-CUS, 29 (5.7%)
presented symptomatic thromboembolic events during follow-up: 2 PE, 7 DVT, 9 SVT recurrences and 11
SVT extensions.
Conclusions: In this study, the SP-CUS detected a few asymptomatic VTC, but failed to identify patients at
risk of thromboembolic events during follow-up. Use of an SP-CUS was therefore neither efﬁcient nor
cost effective.
 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Superﬁcial vein thrombosis (SVT) of the lower limbs is a
common disease, affecting 3e11% of the general population.13 SVT
may be associated with a deep-vein thrombosis (DVT) or isolated.
The incidence of extension to the deep venous system after an
isolated SVT is poorly known.46 In their article published in 2005,
Leon et al.1 emphasise that “patients with SVT require follow-up,
either clinical or with duplex ultrasonography. Compression
ultrasonography (CUS) should be performed at about 7e10 daysecherche sur la Thrombose,
ue Albert Raimond, F-42055
8; fax: þ33 4 77 12 78 20.
Quenet).
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ciety for Vascular Surgery. Publisheafter the original diagnosis to assess the extent and progression of
SVT”. The recent CALISTO study7 assessed the efﬁcacy and safety
of fondaparinux in the treatment of symptomatic, isolated SVT. It
has shown that the risk of symptomatic thromboembolic compli-
cations or death was reduced by the administration of a daily dose
of 2.5 mg of fondaparinux for 45 days. Until these results became
available, the grade of evidence for the antithrombotic treatments
proposed in published guidelines was low8 and several manage-
ment strategies were indicated, comprising various combinations
of treatment, clinical follow-up and a systematic ultrasonographic
examination during follow-up.914
CUS is a quite easily performed and non-invasive imaging
examination, but the systematic use of a follow-up CUS to screen
asymptomatic patients remains controversial. The low event rate ind by Elsevier Ltd. All rights reserved.
Table 1
Patient characteristics at inclusion.
Variable Isolated SVT (N ¼ 537)
Median age (IQR), y 61 (4873)
Age 75 years, n (%) 111 (20.7%)
Women, n (%) 387 (64.5)
Median body mass index (IQR), kg/m2 27.3 (24e30)
BMI > 30 kg/m2, n (%) 159 (29.6%)
Interval between symptom onset and diagnosis
Median interval (IQR), d 5.0 (3e10)
>7 d, n (%) 198 (38.4)
Risk factors, n (%)
Varicose veins 467 (87.0%)
History of venous thromboembolism
SVT 189 (35.2%)
DVT or PE 101 (18.8%)
Family history 172 (32.0%)
Cancer
Active 18 (3.4%)
Previous 25 (4.7%)
Permanent immobility 28 (5.2%)
Chronic cardiac or respiratory insufﬁciency 27 (5.0%)
Known biological thrombophilia 28 (5.2%)
Autoimmune disease 6 (1.1%)
Percentages are calculated on the basis of available data. IQR ¼ interquartile range;
DVT ¼ deep-vein thrombosis; PE ¼ pulmonary embolism; SVT ¼ superﬁcial venous
thrombosis.
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planned CUS (SP-CUS) was envisaged, calls into question the rele-
vance of performing such an examination. Our objective was to
evaluate the efﬁciency of an SP-CUS in patients with isolated SVT.
Material and Methods
Patients
We performed a post hoc analysis of data obtained in the POST
study, a national, multicentre, observational prospective study of
patients with SVT conﬁrmed by CUS. The design and results of this
study have been described in detail elsewhere.15 In brief, patients
older than 18 years with a symptomatic lower-limb SVT at least
5 cm long on CUS were considered for inclusion. Patients who had
undergone surgery under general or loco-regional anaesthesia in
the previous 10 days, those in whom SVT had occurred after scle-
rotherapy within the previous 30 days, and those whose follow-up
was not considered to be feasible, were excluded.
Out of the 600 consecutive patients with objectively conﬁrmed
isolated SVT of the lower limbs included in POST,15 we excluded
patients in whom SP-CUS was not performed and patients who
underwent the SP-CUS before day 8 or after day 15. Then, our study
population consisted of the 537 patients who had undergone
a comprehensive SP-CUS of both lower limbs, including the distal
and proximal deep veins, between 8 and 15 days after the initial
CUS. The study was conducted in accordance with the Declaration
of Helsinki (Hong Kong amendment), Good Clinical Practice
(European Guidelines) and relevant French legal and regulatory
requirements. The protocol was approved by the local Ethics
Committee (Centre Hospitalo-Universitaire, Saint-Etienne, France).
Oral informed consent was obtained from all subjects analysed.
Study outcomes
All patients underwent a comprehensive CUS of both lower
limbs (including proximal and distal deep veins) at entry into the
study. A second CUSwas systematically planned between day 8 and
day 15. The ultrasound assessment was based on a complete CUS
protocol performed and interpreted by vascular medicine physi-
cians having at least 2 years of experience with ultrasound. Using
an adequate set of probes, the proximal veins were examined in
supine or in semi-upright position and the distal veins (including
calf muscular veins) were examined in a sitting position. The great
and small saphenous veins were also examined. The main diag-
nostic criterionwas the compressibility of the vein in the transverse
cross-sectional view by pressing with the probe on the vein at
1e3 cm(s) intervals all along the vein under investigation. Pulsed
Doppler was performed in common femoral veins (CFVs) and in
popliteal veins. Normal and symmetrical breath-induced modula-
tions of the ﬂow in CFV were considered as exclusion criterion for
ilio-caval DVT when the direct US examination of the ilio-caval
veins was not accurate enough. Colour Doppler ﬂow imaging,
grey-scale imaging of the vein in longitudinal view and thrombus
imaging were used as part of the US examination or as secondary
criterion, not as main criterion for diagnosis of vein thrombosis.
Patients were also asked to undergo a further CUS in the event of
new symptoms or signs in the lower limbs during the 3-month
follow-up. The primary clinical outcomes were asymptomatic
venous thrombotic events (extension or recurrence of SVT, DVT of
the lower limbs) diagnosed by the SP-CUS. The secondary outcomes
were symptomatic thromboembolic events (extension or recur-
rence of SVT, DVTof the lower limbs and pulmonary embolism (PE))
up to 3 months. DVT was conﬁrmed by CUS or contrast phlebog-
raphy. DVT was deﬁned as distal DVT when located in the calf, notextended into the popliteal vein and as proximal otherwise. PE was
conﬁrmed by high-probability ventilationeperfusion scan or posi-
tive helical computed tomography scan, or at autopsy. Extension or
recurrence of SVT was conﬁrmed by CUS. Recurrence of SVT was
deﬁned as the occurrence of a new SVT, distinct from the initial
thrombotic event, occurring either in a different superﬁcial vein
from that implicated in the qualifying event, or in the same vein but
clearly differentiated from the initial qualifying event by the pres-
ence of an intervening open venous segment. Extension of SVT was
deﬁned as a proximal extension of SVT by more than 5 cm on CUS.
All events diagnosed as symptomatic thromboembolic events
within the 3-month follow-up periodwere centrally adjudicated by
an independent committee with respect to their symptomatic or
asymptomatic nature. Only conﬁrmed symptomatic events were
retained.
Patients were considered to present an asymptomatic venous
thrombotic event between day 8 and day 15 if the SP-CUS was
positive and no symptomatic thromboembolic event had been
notiﬁed before or on the day of the SP-CUS.
The therapeutic management of patients was not standardised.
All newmedical and surgical treatments prescribed since inclusion
was recorded at the 8e15-day and 3-month follow-up visits.
Data analysis
Qualitative data were reported as numbers and percentages.
Quantitative datawere reported asmedian values with ﬁrst quartile
(Q1) and third quartile (Q3). SAS software, version 9.1 (SAS Institute,
Cary, North Carolina, USA) was used to analyse and process all data.
Results
Population characteristics
A total of 600 consecutive patients with objectively conﬁrmed
SVT of the lower limbs was included in the initial cohort. SP-CUS
was not performed in 24 patients and 39 patients underwent the
SP-CUS before day 8 or after day 15. Finally, a total of 537 patients
with an isolated SVT underwent the SP-CUS. Their demographic
and clinical characteristics are shown in Table 1. The median age of
Table 2
Treatment before and after initial follow-up SP-CUS.
Variable Negative CUS
(N ¼ 507)
Positive CUS
(N ¼ 12)
Treatment before SP-CUS
Anticoagulant treatment 429 (84.6%) 11 (91.7%)
at therapeutic doses 291 7
at prophylactic doses 138 4
NSAID or antiplatelet agent 38 (7.5%) 0
Venotonic drugs, graduated
compression stockings or surgery
25 (4.9%) 1 (8.3%)
No treatment 15 (3.0%) 0
No treatment change after SP-CUS 149 (29.4%) 8 (66.7%)
Anticoagulant at therapeutic doses 85 7
Anticoagulant at prophylactic doses 29 1
NSAID or antiplatelet agent 7 0
Venotonic drugs, graduated
compression stockings or surgery
17 0
No treatment 11 0
Change of treatment after SP-CUS 358 (70.6%) 4 (33.3%)
Anticoagulant treatment (at therapeutic
or prophylactic doses)
16 1
NSAID or antiplatelet agent 28
Venotonic drugs, graduated compression
stockings or surgery
217 3
No treatment 97 0
SP-CUS ¼ systematically planned compression ultrasonography, NSAID ¼
nonsteroidal anti-inﬂammatory drug.
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111 (21%) were at least 75 years old, 159 (30%) were obese (BMI
>30 kg m2) and 349 (65%) were women.
Results of the SP-CUS and 3-month follow-up
A symptomatic thromboembolic event was suspected before or
on the day of the SP-CUS in 18 patients (3.0%). This was conﬁrmed
in 11 patients (four DVT, one recurrence of SVT and six proximal
extensions of SVT). Among the 519 asymptomatic patients (97%)
undergoing the SP-CUS, 12 (2.3%) were found to have experienced
an asymptomatic venous thrombotic event. Four of these events
comprised distal DVT, four were recurrences of SVT and four were
proximal extensions of SVT ranging from 5 to 14 cm (Fig. 1). No
symptomatic thromboembolic event was recorded at 3 months in
any of these 12 patients.
Among the 507 patients with a normal SP-CUS, 29 (5.7%)
experienced a symptomatic thromboembolic event during the
follow-up. Two patients presented a PE and seven patients pre-
sented a DVT (four distal and three proximal). The other 20 patients
presented a recurrent SVT or an extension of the initial SVT.
Pattern of therapeutic management before and after SP-CUS
according to SP-CUS ﬁndings
Before SP-CUS, 440 (85%) of the 519 asymptomatic patients
received anticoagulant treatment (in the form of heparin, heparin
derivatives or a vitamin K agonist) between the initial diagnosis of
SVTand the SP-CUS. Eleven of the 12 patients (92%) inwhom the SP-
CUS revealed an asymptomatic venous thrombotic event received
an anticoagulant treatment versus 429 of the 507 patients (85%),
showing no asymptomatic venous thrombotic event (Table 2).
Among the 12 patients with an asymptomatic venous throm-
botic event revealed by the SP-CUS, the initial treatment remained
unchanged in eight patients (67%) who were already receiving an
anticoagulant. Finally, 9 (75%) of the 12 patients received an anti-
coagulant treatment after SP-CUS.Figure 1. Study ﬂow chart. DVT ¼ deep-vein thrombosis; PE ¼ pulmonary embolism
SVT ¼ superﬁcial venous thrombosis.Regarding the 507 patients showing no asymptomatic venous
thrombotic event on SP-CUS, the initial treatment changed in 358
(71%) patients. Anticoagulant treatment was discontinued in 315
(73%) of the 429 patients with anticoagulant treatment before
SP-CUS. After the SP-CUS, when treatment was changed, it was
purely discontinued in 97 (27%) patients. Among the 29 patients
who experienced a symptomatic thromboembolic event at
3 months, 28 were receiving an antithrombotic drug at the time of
the SP-CUS. Only 11 of these patients continued to receive antico-
agulant treatment after SP-CUS.; pts ¼ patients; SP-CUS ¼ systematically planned compression ultrasonography;
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A total of 52 patients experienced a thromboembolic event,
either symptomatic or asymptomatic, frominclusionuntil the endof
the 3-month follow-up. Twelve of these events were asymptomatic
venous thrombotic events and were identiﬁed by the SP-CUS. The
sensitivity of the SP-CUS is therefore 23%. The remaining 40 were
symptomatic events: 11 occurred before or on the day of the SP-CUS
and 29 occurred after the SP-CUS. These 29 events (56%) were not
and could not have been detected by the SP-CUS.
Discussion
This is the ﬁrst study to assess the clinical relevance of per-
forming an SP-CUS during the follow-up of patients with SVT. We
concentrated on patients who underwent a CUS between day 8 and
day 15 without prior symptoms of thromboembolic events
following the initial SVT.
Bydetectingasymptomatic venous thrombotic events, anSP-CUS
would be relevant if it helped to differentiate high-risk and low-risk
patients or if it led to an appropriate treatment modiﬁcation.
In this study, only a few asymptomatic venous thrombotic
events were detected by SP-CUS (12/519, 2.3%). Among these 12
events, 4 were DVT, all distal. None of these 12 patients experienced
a further symptomatic event.
We cannot be sure what the outcome of these asymptomatic
events would have beenwithout the SP-CUS, but we may postulate
that they would have become symptomatic. However, even if this
hypothesis was correct, the SP-CUS failed to predict all the cases of
symptomatic thromboembolic events occurring up to 3 months,
missing 29 (56%) of the 52 venous thromboembolic events actually
recorded at this time.
Hence, the SP-CUS failed to fully identify patients at risk of
thromboembolic events during the follow-up, possibly because it
led to inappropriate treatment modiﬁcations.
The clinical relevance and cost-effectiveness of performing an
SP-CUS appear to be questionable. This is reﬂected by the pattern of
therapeutic management following the SP-CUS. In most cases,
detection of an asymptomatic venous thrombotic event by the SP-
CUS did not lead to modiﬁcation of the initial treatment. The initial
treatment remained unchanged in 8 of the 12 patients (67%) in
whom an asymptomatic venous thrombotic event was detected, all
these patients continuing to receive anticoagulants. Of note, among
the 12 asymptomatic venous thrombotic events diagnosed by the
SP-CUS, only four involved extension to the deep venous system, all
at a distal location, a situation for which there are no clear treat-
ment guidelines. A positive SP-CUS may prompt a more aggressive
therapy, even though no speciﬁc treatment has so far been vali-
dated in this situation.
By contrast, when no new venous thrombotic event was diag-
nosed by the SP-CUS, anticoagulant treatment was discontinued in
303 (71%) of the 429 patients initially treated with such drugs. The
majority of the patients experiencing thromboembolic events
during the follow-up had had their anticoagulant treatment
prematurely discontinued after a negative SP-CUS. Therefore, it
seems that the SP-CUS provided false reassurance to the physicians.
Indeed, in the CALISTO study, no modiﬁcation of treatment
(placebo or fondaparinux at prophylactic dose) was planned on the
basis of the intermediate evaluation in the absence of any clinical
sign. Interestingly, the rate of symptomatic DVT at 77 days was 1.3%
(0.7e1.9) in the placebo group, close to the incidence of symp-
tomatic DVT at 3 months in this study (2.1% (0.8e3.3)). In our study,
the SP-CUS evidently did not lead to an appropriate treatment
modiﬁcation in the sense that the overall outcome of the patients
was no better than in the placebo group of the CALISTO study.7Our results are in accordance with the absence of any recom-
mendation in current guidelines8 for an SP-CUS in patients pre-
senting no new clinical signs.
In view of the cost of a CUS and the low rate of venous throm-
boembolic events, this form of therapeutic management does not
seem to be cost effective.
This study is only descriptive. Ideally, to assess the relevance of
performing an SP-CUS during the follow-up of patients with SVT,
the use of this examination should have been randomised. Most of
the patients included in the POST study received an anticoagulant
treatment for their initial SVT, various treatment regimens being
used. This precludes any conclusions concerning therapy. The very
recent results of the CALISTO study7 conﬁrm that fondaparinux
administered at prophylactic doses is effective and safe even in the
absence of an SP-CUS. Thus, in the future, most patients with an
isolated SVT will probably receive an anticoagulant treatment.
Conclusion
The use of an SP-CUS is neither efﬁcient nor cost effective. Our
results indicate the absence of any need for this examination.
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